- Home
- AGEN vs FGMC Comparison
AGEN vs FGMC Comparison
Compare AGEN & FGMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FGMC
- Stock Information
- Founded
- AGEN 1994
- FGMC 2023
- Country
- AGEN United States
- FGMC United States
- Employees
- AGEN N/A
- FGMC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FGMC
- Sector
- AGEN Health Care
- FGMC
- Exchange
- AGEN Nasdaq
- FGMC NYSE
- Market Cap
- AGEN 87.7M
- FGMC 100.6M
- IPO Year
- AGEN 2000
- FGMC 2025
- Fundamental
- Price
- AGEN $5.16
- FGMC $9.82
- Analyst Decision
- AGEN Buy
- FGMC
- Analyst Count
- AGEN 4
- FGMC 0
- Target Price
- AGEN $13.00
- FGMC N/A
- AVG Volume (30 Days)
- AGEN 1.6M
- FGMC 43.5K
- Earning Date
- AGEN 08-07-2025
- FGMC 01-01-0001
- Dividend Yield
- AGEN N/A
- FGMC N/A
- EPS Growth
- AGEN N/A
- FGMC N/A
- EPS
- AGEN N/A
- FGMC 0.08
- Revenue
- AGEN $99,524,000.00
- FGMC N/A
- Revenue This Year
- AGEN $14.49
- FGMC N/A
- Revenue Next Year
- AGEN N/A
- FGMC N/A
- P/E Ratio
- AGEN N/A
- FGMC $571.77
- Revenue Growth
- AGEN N/A
- FGMC N/A
- 52 Week Low
- AGEN $1.38
- FGMC $9.53
- 52 Week High
- AGEN $18.74
- FGMC $9.85
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- FGMC N/A
- Support Level
- AGEN $5.06
- FGMC N/A
- Resistance Level
- AGEN $6.35
- FGMC N/A
- Average True Range (ATR)
- AGEN 0.59
- FGMC 0.00
- MACD
- AGEN 0.12
- FGMC 0.00
- Stochastic Oscillator
- AGEN 65.00
- FGMC 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).